[ad_1]
S"It's absolutely fantastic now to see the very first evidence that ribociclib can give thousands of younger women with metastatic bad cancer more time to live. We can not define in words what it will mean for so many women to be able to spend precious extra time with their families and create memories that will last a lifetime. "
She said the new clbad of drugs was "one of the biggest advances in bad cancer research in recent decades."
"It is essential that we ensure that all patients who can benefit from it can access it," she said.
This treatment could benefit 1,500 pre-menopausal women annually with advanced cancer.
Since last year, the NHS has recommended the drug for such cases. But experts say only about half are currently receiving it.
The drug would normally cost £ 35,000 per year per patient. However, the NHS has negotiated a lower and undisclosed price for treatment.
Taken daily, ribociclib prevents cancer cells from dividing and spreading by blocking the action of two key proteins. The clinical trials involved patients with advanced advanced / advanced HER2-negative disease – the most common type of incurable bad cancer. They also received injections to suppress their estrogen levels.
Dr. Sara A. Hurvitz, lead author of the California Jonsson Comprehensive Cancer Treatment Center study, said, "This is the first study to show improved survival for any targeted treatment when used with a endocrine therapy as a first-line treatment for advanced bad cancer.
"The use of ribociclib as a first-line treatment has significantly extended overall survival, which is good news for women with this terrible disease."
Dr. Jason Carroll, Breast Cancer Specialist at the Cambridge Institute of Cancer Research UK, said, "This is the first time we have seen the administration of new types of drugs called CDK4 / 6 inhibitors, along with standard treatment, can improve the overall survival of pre-treated patients. postmenopausal women with bad cancer. This is a great example of how understanding the underlying biology of cancer can make a big difference for patients. "
Dr. Harold J. Burstein, of ASCO, said, "Advanced bad cancer in pre-menopausal women can be very aggressive. It is important and encouraging to see targeted therapy that dramatically increases the survival of younger women with this disease. "
[ad_2]
Source link
